Literature DB >> 20518718

Development and application of 'phosphoflow' as a tool for immunomonitoring.

Sheng Wu1, Lei Jin, Luis Vence, Laszlo G Radvanyi.   

Abstract

Flow cytometry has revolutionized our ability to monitor immune responses by allowing us to simultaneously track a variety of cell surface and intracellular markers in discrete cell subsets in a highly sensitive and reproducible manner. This is especially critical in this new era of vaccinology trying to tackle the growing problems of chronic viral infections and cancer that not only evade host immune responses, but can negatively manipulate vaccine-induced immune responses. Thus, understanding how lymphocyte signaling is altered under normal and pathological conditions has become more critical. Over the last decade, a new flow cytometry technology called 'phosphoflow' (also sometimes called 'phosflow'), is rapidly developing for tracking multiple intracellular signaling molecules in the immune system at a single-cell level. Antibodies and reagents for tracking both tyrosine-phosphorylated and serine/threonine-phosphorylated signaling intermediaries in key immune signaling pathways have been developed, and phosphoflow is now starting to be applied to a wide variety of both preclinical and clinical studies on lymphocyte responses, as well as the functioning of cancer cells and virally infected cells. Here, we review the development of phosphoflow technology, its modern applications in the field of immunomonitoring and its current limitations. We then provide a perspective on the future of phosphoflow and a vision of how it can be applied to emerging critical questions in human vaccinology and public health.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20518718      PMCID: PMC2933839          DOI: 10.1586/erv.10.59

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  71 in total

1.  PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV.

Authors:  Debora Franceschini; Marino Paroli; Vittorio Francavilla; Melissa Videtta; Stefania Morrone; Giancarlo Labbadia; Antonella Cerino; Mario U Mondelli; Vincenzo Barnaba
Journal:  J Clin Invest       Date:  2009-02-23       Impact factor: 14.808

Review 2.  T cell activation.

Authors:  Jennifer E Smith-Garvin; Gary A Koretzky; Martha S Jordan
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

3.  Functional proteomic profiling of AML predicts response and survival.

Authors:  Steven M Kornblau; Raoul Tibes; Yi Hua Qiu; Wenjing Chen; Hagop M Kantarjian; Michael Andreeff; Kevin R Coombes; Gordon B Mills
Journal:  Blood       Date:  2008-10-07       Impact factor: 22.113

4.  Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients.

Authors:  James H Finke; Brian Rini; Joanna Ireland; Patricia Rayman; Amy Richmond; Ali Golshayan; Laura Wood; Paul Elson; Jorge Garcia; Robert Dreicer; Ronald Bukowski
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

5.  Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates.

Authors:  Nikesh Kotecha; Nikki J Flores; Jonathan M Irish; Erin F Simonds; Debbie S Sakai; Sophie Archambeault; Ernesto Diaz-Flores; Marc Coram; Kevin M Shannon; Garry P Nolan; Mignon L Loh
Journal:  Cancer Cell       Date:  2008-10-07       Impact factor: 31.743

6.  Astrocytic regulation of human monocytic/microglial activation.

Authors:  Alex M Kostianovsky; Lisa M Maier; Richard C Anderson; Jeffrey N Bruce; David E Anderson
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

7.  STAT-3 and ERK 1/2 phosphorylation are critical for T-cell alloactivation and graft-versus-host disease.

Authors:  Sydney X Lu; Onder Alpdogan; Janine Lin; Robert Balderas; Roberto Campos-Gonzalez; Xiao Wang; Guo-Jian Gao; David Suh; Christopher King; Melanie Chow; Odette M Smith; Vanessa M Hubbard; Johanne L Bautista; Javier Cabrera-Perez; Johannes L Zakrzewski; Adam A Kochman; Andrew Chow; Gregoire Altan-Bonnet; Marcel R M van den Brink
Journal:  Blood       Date:  2008-10-06       Impact factor: 22.113

8.  A novel CCR5-specific pharmacodynamic assay in whole blood using phosphoflow cytometry highlights different ligand-dependent responses but similar properties of antagonists in CD8+ and CD4+ T lymphocytes.

Authors:  Martin E Dahl; Amy Berson; Jose Lora; Maria Fuentes
Journal:  J Pharmacol Exp Ther       Date:  2008-08-27       Impact factor: 4.030

Review 9.  Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).

Authors:  Jeffrey Weber
Journal:  Oncologist       Date:  2008

10.  A prescription for human immunology.

Authors:  Mark M Davis
Journal:  Immunity       Date:  2008-12-19       Impact factor: 31.745

View more
  13 in total

Review 1.  Imaging flow cytometry: coping with heterogeneity in biological systems.

Authors:  Natasha S Barteneva; Elizaveta Fasler-Kan; Ivan A Vorobjev
Journal:  J Histochem Cytochem       Date:  2012-06-27       Impact factor: 2.479

2.  Methods to measure vaccine immunity.

Authors:  Vasso Apostolopoulos; Francesco M Marincola
Journal:  Expert Rev Vaccines       Date:  2010-06       Impact factor: 5.217

3.  POGZ promotes homology-directed DNA repair in an HP1-dependent manner.

Authors:  John Heath; Estelle Simo Cheyou; Steven Findlay; Vincent M Luo; Edgar Pinedo Carpio; Jeesan Lee; Billel Djerir; Xiaoru Chen; Théo Morin; Benjamin Lebeau; Martin Karam; Halil Bagci; Damien Grapton; Josie Ursini-Siegel; Jean-Francois Côté; Michael Witcher; Stéphane Richard; Alexandre Maréchal; Alexandre Orthwein
Journal:  EMBO Rep       Date:  2021-11-10       Impact factor: 9.071

Review 4.  Diagnostic Tools for Inborn Errors of Human Immunity (Primary Immunodeficiencies and Immune Dysregulatory Diseases).

Authors:  Annely M Richardson; Ann M Moyer; Linda Hasadsri; Roshini S Abraham
Journal:  Curr Allergy Asthma Rep       Date:  2018-02-22       Impact factor: 4.806

5.  Preservation of lymphocyte functional fitness in perinatally-infected and treated HIV+ pediatric patients displaying sub-optimal viral control.

Authors:  Aaruni Khanolkar; William J Muller; Bridget M Simpson; Jillian Cerullo; Ruth Williams; Sun Bae Sowers; Kiana Matthews; Sara Mercader; Carole J Hickman; Richard T D'Aquila; Guorong Liu
Journal:  Commun Med (Lond)       Date:  2022-03-04

6.  Mathematical modeling of oncogenesis control in mature T-cell populations.

Authors:  Sebastian Gerdes; Sebastian Newrzela; Ingmar Glauche; Dorothee von Laer; Martin-Leo Hansmann; Ingo Roeder
Journal:  Front Immunol       Date:  2013-11-21       Impact factor: 7.561

7.  Scrutinizing calcium flux oscillations in T lymphocytes to deduce the strength of stimulus.

Authors:  Susan N Christo; Kerrilyn R Diener; Robert E Nordon; Michael P Brown; Hans J Griesser; Krasimir Vasilev; Farid C Christo; John D Hayball
Journal:  Sci Rep       Date:  2015-01-14       Impact factor: 4.379

8.  Phospho-specific flow cytometry for pharmacodynamic monitoring of immunosuppressive therapy in transplantation.

Authors:  Carla Baan; Anne Bouvy; Ramin Vafadari; Willem Weimar
Journal:  Transplant Res       Date:  2012-11-16

9.  Flow cytometric detection of p38 MAPK phosphorylation and intracellular cytokine expression in peripheral blood subpopulations from patients with autoimmune rheumatic diseases.

Authors:  Athanasios Mavropoulos; Dimitrios P Bogdanos; Christos Liaskos; Timoklia Orfanidou; Theodora Simopoulou; Efterpi Zafiriou; Lazaros I Sakkas; Eirini I Rigopoulou
Journal:  J Immunol Res       Date:  2014-02-03       Impact factor: 4.818

10.  Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients.

Authors:  Richard G Everson; Richard M Jin; Xiaoyan Wang; Michael Safaee; Rudi Scharnweber; Dominique N Lisiero; Horacio Soto; Linda M Liau; Robert M Prins
Journal:  J Immunother Cancer       Date:  2014-05-13       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.